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ABSTRACT

Amoebiasis is defined as an intestinal infection with the human protozoan
parasite, Entamoeba histolytica; approximately 100,000 deaths annually can be
attributed to amoebiasis. Disease states range from asymptomatic colonization to
invasive amoebiasis, characterized by abdominal pain and dysentery. Dissemination to
extraintestinal sites, such as the liver and/or brain, can occur. Vesicle trafficking is
critical for parasite virulence, and multiple signaling cascades within the pathogen
facilitate these events.
One important regulator of signal transduction is the tightly controlled PI 3kinase (PI3K), which phosphorylates the lipid, phosphatidylinositol bisphosphate (PIP2),
producing phosphatidylinositol trisphosphate (PIP3). Effector proteins, such as Akt, are
recruited to the signaling complex, where they initiate downstream signal events. These
effector proteins often possess lipid binding domains specific for PIP3, such as the
Pleckstrin homology (PH) domain. In mammalian cells, PI3K signaling pathways play a
role in the prevention of apoptosis, a type of programmed cell death (PCD). Like
mammalian cells, several unicellular eukaryotic organisms, including E. histolytica,
undergo PCD in response to stimuli such as exposure to reactive oxygen species or
drugs. Interestingly, metronidazole (MTZ), the DNA damaging drug commonly used to
treat E. histolytica infections, can induce PCD in another protozoan, Blastocystis
hominis.
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Recently, an E. histolytica cell line expressing GFP-labeled PHBTK was generated,
which exhibited a PI3K dominant-negative phenotype (PI3K-DN), presumably because
the binding of PHBTK to PIP3 prevents binding and signaling by physiologically relevant
proteins. In the current study, we investigated the effectiveness of MTZ on the E.
histolytica PI3K-DN cell line. Because at least one organism undergoes PCD in response
to the DNA damaging drug, MTZ, and since PI3Ks are involved in cell survival signals in
mammalian cells, we hypothesized that E. histolytica cells expressing GFP-PHBTK,
putatively deficient in cell survival signals, may represent a cell line that is more
susceptible to MTZ killing. We found that cells expressing GFP-PHBTK were resistant to
MTZ killing, refuting our initial hypothesis.
Therefore, we investigated the connection between PI3K-DN signaling and
resistance to MTZ. Wildtype cells treated with a chemical PI3K inhibitor displayed
increased MTZ resistance. Known MTZ resistance mechanisms, including expression of
multidrug resistant pumps and increased levels of superoxide dismutase, were not
related to expression of GFP-PHBTK.

Interestingly, we found that MTZ induced

phenotypes associated with PCD in both wildtype E. histolytica cells and cells expressing
GFP-PHBTK. This is the first report that demonstrates that inhibition of PI3Ks contributes
to MTZ resistance in E. histolytica, and the first report that shows MTZ can induce PCD in
the parasite.
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CHAPTER 1
LITERATURE REVIEW
I. Entamoeba histolytica
Introduction, transmission, and epidemiology
Amoebiasis is defined as an intestinal infection with the human protozoan
parasite, Entamoeba histolytica (40). E. histolytica was first recognized in 1875 by Fedor
Losch, and was generically named Entamoeba by Schaudinn in 1903 (reviewed in (17)).
By 1913, the life cycle and morphology of the amoeba had been described (17): E.
histolytica exists in two forms: cyst and trophozoite (Fig. 1.1).
Early in recorded medical history, it was observed that certain patients harbored
E. histolytica, but did not exhibit symptoms. In 1925, Brumpt proposed that there were
two morphologically identical species capable of colonizing the gastrointestinal tract, E.
histolytica (then called Entamoeba dysenteriae) and E. dispar, and that only the former
was pathogenic (17). Based on contributions by Tannich (36), and Clark and Diamond
(8), among many others, it is now widely accepted that there are at least two distinct
Entamoeba species (17). The ability to distinguish the pathogenic and non-pathogenic
species of Entamoeba has had broad clinical and epidemiological implications (reviewed
in (42)).
Throughout the 1980’s and early 1990’s, it was estimated that 10% of the
world’s population was infected with E. histolytica and that these infections accounted
for as many as 100,000 deaths per year (reviewed in (1, 42)). However, the combination
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of more accurate diagnostic techniques (1, 42) and the above-mentioned division of
Entamoeba species (17) has resulted in the need to re-evaluate epidemiological impact
of amoebiasis. Furthermore, it is now recognized that a third morphologically identical
Entamoeba species, Entamoeba moshkovskii (also believed to be non-pathogenic) is
commonly found in areas of E. histolytica endemnicity (1). Therefore, the wide range of
disease outcomes that was once attributed to variable virulence of E. histolytica is now
believed to be caused in part, by human colonization with two or three Entamoeba
species. Importantly, the estimated deaths are all likely attributed to E. histolytica, the
only one considered to be a human pathogen (40). Furthermore, the World Health
Organization estimates that four billion cases of diarrheal disease kill 2.2 million people
each year, and account for 15% of all childhood deaths in developing countries (41),
leaving little doubt that understanding and treating parasites and other microorganisms
that cause such diseases should be a high priority.
The environmentally stable cyst form of E. histolytica is ingested from
contaminated food or water. The cyst withstands the harsh conditions of the stomach
and passes through to the intestinal tract, where excystation takes place. Amoeboid
trophozoites colonize the large intestine, using bacteria and human erythrocytes as food
sources. The trophozoites can re-encyst and be excreted into the feces, thus completing
the life cycle (reviewed in (19, 30)) (Fig. 1.1).

2

Figure 1.1 Life cycle of E. histolytica.
Image credited to Mariana Ruiz Villarreal and released to the public domain via
www.wikipedia.org. Infections start with the ingestion of cysts via contaminated food
or water. After passing through the stomach, the trophozoites excyst and colonize the
intestinal tract. Occassionally, trophozoites breach the mucosal lining of the intestines,
leading to invasive infections. Trophozoites can re-encyst in the intestinal tract, and
cysts are released in the feces.
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The symptoms associated with infection vary widely, and can range from
asymptomatic colonization to invasive amoebiasis, in which the intestinal mucosal layer
is breached by the amoeba, resulting in abdominal pain and bloody diarrhea (19, 30).
Necrotizing colitis can develop from intestinal infections, and is often fatal; other
complications include the formation of amoebomas, bowel obstruction, shock, or death
(30). Rarely, the infection can spread to other organs, including the liver (40). Patients
with amoebic liver abscess (ALA) often display symptoms including fevers, chills, and
sweating (30). Although rare, the amoebae can metastasize to other sites, including the
spleen, lungs, and/or brain, a complication that is associated with high rates of mortality
(30).
Because new tools for proper identification of Entamoeba species have been in
use for a relatively short period of time, obtaining accurate epidemiological data is
difficult. However, one can estimate the impact of amoebiasis by using site studies of
particular geographic regions. For example, a group of children in Bangladesh, aged two
to five years, were enrolled in a surveillance study that spanned four years. Eighty
percent of the children who participated for the full length of the study were infected
with E. histolytica at least once during four years, and of those infected, 25% developed
diarrhea and 15% developed dysentery during the study period (14). In addition, an
ELISA based study found that 8.4% of the general population of Mexico may be infected
with E. histolytica, and a PCR based study of asymptomatic Vietnamese adults found
that 11.2% of that population was infected (1). Importantly, certain populations within
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these regions seem to be at higher risk than others for infections with E. histolytica. For
example, it is estimated that infection rates in pregnant women in Mexico are between
22.5 and 35% (42). Furthermore, the severity of disease varies with geographic region;
patients in Vietnam exhibit remarkably high numbers of ALAs (42).
Since disease burden and severity varies widely from region to region, some
have suggested that particularly virulent strains of E. histolytica are differentially
distributed. In fact, the genetic diversity of E. histolytica strains has been observed (42).
In addition, a recent study examined the genotype of E. histolytica strains within the
same individual. Samples obtained from the intestines and from ALAs were genotyped,
and in all 18 cases, the genotypes of the samples from different sites were found to be
different within the same individual (2).

While understanding the genetics of E.

histolytica is indeed important, host characteristics that influence susceptibility and
virulence should also be examined (42).
The World Health Organization estimates that 1.1 billion people have no access
to clean water and 2.4 billion people have no access to sanitation (41). Therefore, the
risk of acquiring an infection with E. histolytica is particularly high in areas of
endemnicity, including Mexico, India, South Africa, and areas of Central America, South
America, and Asia (42), where there is little basic infrastructure. In addition, the NIH has
categorized E. histolytica as a Category B bioterrorism agent, because it is genetically
tractable and could be disseminated relatively easily via water supplies. Therefore, the
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development of effective treatments and/or a vaccine is necessary to reduce the
disease and deaths caused by amoebiasis.
Diagnosis of E. histolytica infection
Because it is believed that E. histolytica is the only pathogenic species of
Entamoeba, the WHO has recommended that a definitive diagnosis be made before
treatment is administered when amoebiasis is suspected (40). Furthermore, the WHO
has determined that chemoprophylaxis is never appropriate for amoebiasis (40). As
mentioned above, microscopic examination cannot distinguish between infections with
E. histolytica or E. dispar. If microscopy is the only diagnostic tool available, WHO
guidelines recommend that no treatment should be given unless individuals display
other symptoms characteristic of amoebiasis (40). For example, high specific antibody
titers and/or microscopic observation of trophozoites with ingested red blood cells are
highly associated with invasive disease. Even then, other disease causes should be
explored. For example, in 9% of children in the Bangladesh cohort (described above)
that were subjected to a comprehensive series of microbiological tests, co-infections
with Shigella and Campylobacter were identified (14).
Recently, great strides have been made in improving the accuracy of testing for
amoebiasis. As microscopy has fallen out of favor, tests requiring parasite cultures or
isoenzyme analysis have come and gone as potential diagnostic tools, largely because of
technical difficulties, lack of reliability, and costs (10). In addition, PCR, real-time PCR,
and microarray based methods are routinely used in research laboratories, but have not
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been employed widely in a clinical setting. In particular, the technical difficulties
involved in harvesting DNA from stool samples and the costs of methods that require
nucleic acid isolation prevent practical clinical applications, especially in the field, and
especially in developing countries (10, 21).
In industrialized nations, the standard clinical test is an ELISA based antibody test
that detects the presence of human IgG which is capable of binding to a recombinant E.
histolytica-specific protein, LecA (21). This test is less useful in areas of endemnicity,
where patients have likely been exposed to E. histolytica during their lifetimes; such
exposure may result in a positive antibody test in the absence of an infection (10).
However, ELISAs that detect specific E. histolytica antigen (e.g., lectin) have proven to be
reliable (10). While the E. histolytica antigen test is less sensitive and specific than PCRbased methods (21), ELISAs are quick and relatively simple to perform, even in
laboratories that lack molecular facilities, making them a feasible diagnostic tool in
areas of endemnicity (10).
Despite the progress in diagnostic methods, in many areas of endemnicity,
microscopic examination of stool is still the “gold standard.” Furthermore, it is standard
practice to treat all cyst passers with anti-protozoal drugs, with or without symptoms.
Not only do these practices lead to unnecessary treatments, but prolonged exposure to
sub-lethal prophylactic doses of drugs also creates conditions that favor resistance (10,
37, also see a review of drug resistance below).
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Immune response and vaccine development
Despite the availability of effective drug therapies (see a review below), infection
and mortality rates have remained relatively constant, demonstrating a need for
prevention of amoebiasis (10).

To this end, much research has focused on the

development of an E. histolytica vaccine. The potential for the human immune system
to self-correct an invasion by E. histolytica is high, given that approximately 80 to 90% of
infections resolve themselves with no or non-specific symptoms (reviewed in (12)). It is
believed that human hosts employ a variety of innate immune mechanisms to combat E.
histolytica infections; the first line of defense is the epithelial and mucosal barrier of the
intestinal tract (12).

In addition, granulocytes and phagocytic immune cells are

dispatched to the site of an E. histolytica infection (12).
Therefore, understanding the interactions between E. histolytica and the host
immune system is an important first step in vaccine development. For example, it has
been established that E. histolytica infections induce the production of specific
antibodies in 81-100% of patients (12). A study of children in Bangladesh found that the
production of mucosal antibodies directed towards one of the parasite’s adhesion
proteins, Gal/GalNac lectin, protects from infection and disease (12). Although other
virulence proteins have been studied as vaccine candidates, Gal/GalNac lectin seems to
have the best potential. In addition, the host’s cell-mediated cytokine response has
been studied; in particular, IFN-γ has an important role in protecting a host from
diarrhea caused by E. histolytica (11, 22). As we gain a better understanding of the
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combination of host immune responses involved, we will have a better chance of
developing a successful vaccine.
Because Gal/GalNac lectin has become accepted as the best vaccine target,
recent studies have focused on the best delivery system for a vaccine. One group has
used a rodent model to investigate an oral vaccine that utilizes the attenuated Yersinia
enterocolitica type III secretion system as a Gal/GalNac antigen delivery mechanism, and
these researchers reported limited success in the prevention of ALA (22).

More

recently, Guo et al. neutralized IFN-γ in mice immunized with a bacterially expressed
Gal/GalNac lectin subunit, and reported that this blocked any vaccine protection,
supporting the role of this cytokine in the host’s immune response to E. histolytica (11).
Although significant progress has been made towards vaccine development, clinicians
do not yet have this tool in their arsenals.
Drug therapies and resistance
In the absence of a vaccine, E. histolytica infections must be treated with
antibiotics, and recommended treatment regimens depend largely on the manifestation
of disease. There are two basic classes of drugs that are traditionally used in the
treatment of amoebiasis: luminal amoebicides and tissue amoebicides. Asymptomatic
individuals are typically treated only with luminal amoebicides, such as paramomycin or
diloxanide furoate. Invasive disease or extraintestinal infections, such as ALAs, are
treated with tissue amoebicides, such as metronidazole (MTZ), followed by treatment
with a luminal amoebicide (30). Occassionally, surgery is required to repair intestinal
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damage, but is rarely recommended for treatment of ALA. No guidelines are available
for treatment of disease that has spread beyond the intestinal tract or liver (30).
MTZ has advantages and disadvantages. It is relatively inexpensive, and is welltolerated at lower dosages; some patients report a metallic taste after taking MTZ (34).
However, patients receiving higher doses or long-term therapy can experience nausea,
diarrhea, and neurotoxicity (34).

Furthermore, MTZ crosses the placenta, and is

contraindicated during the first trimester of pregnancy because of its mutagenic
potential. In addition, women who are breastfeeding should not be given MTZ since the
drug is found in breastmilk (28, 34). Significantly, the majority of MTZ is absorbed in the
small intestine: approximately 6.8% of MTZ is absorbed in the colon (16); the future
development of drugs that are more specifically targeted to the site of infection may be
more effective amoebiasis treatments.
Some advances have been made toward the development of new drug
therapies. For example, nitazoxanide has recently been evaluated for its effectiveness
against amoebiasis (30). A double blind study of a cohort of patients in Egypt found that
94% of nitazoxanide-treated patients were free of E. histolytica in two post-treatment
stool samples, compared to 50% of those taking a placebo. Furthermore, this drug
successfully relieved the symptoms of 100% of the patients who were treated for ALA
(32). This drug has numerous potential advantages compared to MTZ. Since it is
effective in eradicating trophozoites from the intestinal tract and can treat invasive
infections in both the intestinal tract and the liver, the use of nitazoxanide could reduce
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treatment times and costs (32). Furthermore, it is approved for use in children as young
as twelve months, and because it is effective against a wide variety of enteric pathogens
(9, 15, 32), it has the potential to be prescribed when reliable diagnostic tools are not
available (e.g., in developing countries). To this end, Diaz et al. reported that when used
as a broad-spectrum treatment for mixed parasite infections, this drug was tolerated
with no serious side effects, and was effective at eliminating 84% of infections with
protozoans and 95% of helminths (9). Despite the research in this area, MTZ is still the
most commonly used drug to treat infections with E. histolytica, Trichomonas vaginalis,
and Giardia (5).
Treatment failures associated with MTZ have been reported. However, it is
important to note that these failures may have been caused by the lack of an
appropriate diagnosis, rather than the drug itself. For example, in 1974, a Vietnam
veteran was treated for amoebiasis using the standard MTZ treatment regimen.
Although patient compliance could not be verified, treatment was deemed successful
because following MTZ therapy, no E. histolytica was found in the stool, and the patient
reported no more symptoms during the following six month period. Eight months after
“successful” treatment, the patient was treated again for ALA (28). In this case, the ALA
was resolved using an appropriate MTZ treatment regimen (in addition to chloroquine).
This particular case highlights the need for methods to diagnose early-stage hepatic
amoebiasis. Since the time of this case study, it has been well-established that ALA can
occur months or years after infection, often with no intestinal symptoms (30).
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Fortunately, little clinical resistance to MTZ by E. histolytica has been observed
(3). MTZ sensitivity among clinical isolates is variable, and a higher IC50 value has been
reported for many clinical isolates of E. histolytica as compared to the laboratory
reference strain HM1:IMSS (3). However, for infections with Giardia, the prevalence of
clinical MTZ resistance has been reported to be as high as 20% (37). In addition, MTZ
resistance in Trichomonas vaginalis was first reported in 1962 (37).

Therefore,

mechanisms of MTZ resistance have been well-studied in these parasites.
In order to understand what allows a parasite to evade MTZ, one must first
understand the mechanism of action of the drug itself. MTZ is considered a prodrug,
and it is active only when it is reduced by the metabolic activities of the target cell. In
particular, luminal parasites utilize a pathway by which pyruvate:ferridoxin
oxidoreductase (PFOR) reduces ferredoxin, which then reduces NAD+. Alternatively,
MTZ can be reduced by PFOR, resulting in drug activation (33) (Fig. 1.2). After activation,
MTZ binds to DNA and proteins, causing irreversible damage (33). Because most higher
eukaryotic cells (such as those in humans) lack PFOR or do not rely heavily on metabolic
pathways that use enzymes such as PFOR, MTZ is not activated and does not cause cell
damage.
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Figure 1.2. Predicted MTZ activation pathway in unicellular protozoan parasites.
MTZ is converted from a pro-drug to its active form as a result of the metabolic activities
of protozoan parasites. It is believed that ferredoxin reduces MTZ instead of its typical
target, NAD+. Once reduced, MTZ is activated, and causes damage to DNA and proteins
in the cell.
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MTZ resistance in trichomonads and Giardia has been associated with changes in
activity and/or expression levels of enzymes involved in these “MTZ activation”
metabolic pathways, effectively blocking the activation of the drug (5). For example,
MTZ-resistant Giardia exhibits reduced PFOR activity and downregulation of ferredoxin I
(37) and MTZ-resistant trichimonads display reduced levels of PFOR and ferredoxin (37).
Some studies have suggested that E. histolytica has no alternatives to these metabolic
pathways, and that this may explain the lack of observed clinical MTZ resistance in E.
histolytica (33).
Despite the lack of clinically MTZ-resistant E. histolytica strains, step-wise
increases in MTZ exposure have resulted in the induction of resistance in two axenic
laboratory strains of E. histolytica, HM-1:IMSS and HTH-56:MUTM (3). The mechanism
of resistance has been characterized in these cell lines, and changes in metabolism have
been observed. For example, MTZ-resistant parasites expressed three to five times as
much iron-containing superoxide disumutase (3, 33). However, the activity of PFOR was
not significantly altered. Like Giardia, ferredoxin 1 expresssion decreased (37). These
data invite the question: if E. histolytica does not alter the “traditional” MTZ activation
pathway to become resistant, are there other pathways that activate MTZ?

For

example, Pal et al. recently reported that E. histolytica possesses nitroimidazole
reductase genes, which confer resistance to MTZ in transformed bacteria (26). Can MTZ
cause cell death in ways unrelated to metabolic changes? (See a review of cell death
mechanisms in Part II.)

A complete understanding of MTZ resistance mechanisms in E.
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histolytica is important.

Even if clinical resistance is not presently observed, the

background knowledge will be valuable as new drugs are developed to treat amoebiasis
(37).
In addition to the MTZ-resistant E. histolytica laboratory strains, a mass random
mutagenesis study, which utilized the chemical mutagen, ethyl methanesulfonate,
identified an E. histolytica laboratory strain that was resistant to emetine (a now seldom
used treatment for amoebiasis), and this particular strain has been used extensively to
study drug resistance mechanisms in E. histolytica (3). The emetine-resistant laboratory
strain shows increases in the expression of mRNA for EhPgp1 and EhPgp5, two genes
encoding P-glycoproteins (Pgps), a type of drug-excluding membrane pump (3). E.
histolytica possesses at least six Pgp like genes, EhPgp1-EhPgp6. Drug resistance in
bacteria, mammalian tumor cells, and some protozoan parasites is sometimes
associated with the overexpression or overactivity of Pgp pumps, also known as ATPbinding cassette (ABC) pumps or multidrug resistance (MDR) pumps (5, 37). The
chemotherapeutic agents are actively transported out of the cells; this energydependent process can be inhibited by calcium channel blockers, such as verapamil (4).
Recently, an RT-PCR based study of clinical isolates of E. histolytica in India
attempted to correlate the lack of EhPgp1 mRNA expression with a lack of MTZ
resistance in clinical settings. Indeed, the researchers found no expression of EhPgp1
mRNA in the clinical isolates they tested (4). However, it has been hypothesized that
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unlike emetine, MTZ is not a substrate of such pumps (33). Therefore, this study may
not fully represent the potential for clinical MTZ resistance by E. histolytica.
Of note, it has been presumed that the use of laboratory strains that are
transfected with exogenous plasmids does not affect clinical drug resistance, mostly
because plasmids usually confer resistance to antibiotics not typically used to treat
patients. However, it is worth noting that Leishmania cells expressing a plasmid that
conferred resistance to G418 (a commonly used plasmid resistance marker) were crossresistant to paromomycin, a drug used to treat patients. This observation emphasizes
the need to understand all resistance mechanisms: seemingly irrelevant “laboratoryinduced” drug resistance mechanisms may provide insight into clinical resistance (5).

II. Programmed cell death
Categories of cell death
Several mechanisms of cell death have been described, and these include
necrosis, autophagy, apoptosis, and programmed cell death (PCD) (23). Others classify
apoptosis and autophagy as types of PCD (Type I and Type II, respectively) (6). To
further complicate matters, some authors define apoptosis and PCD as different
processes (although the terms are often used interchangeably), since PCD during
development can occur without apoptotic features (23).
To an extent, the types of cell death can be categorized by their morphological
characteristics. For example, necrotic cells have a swollen cytoplasm, display defects in
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membrane integrity, have ruptured organelles, and may display condensed chromatin
(23).

Apoptosis, a type of PCD often associated with activation of a caspase cascade,

causes several different morphological changes in a cell. In the early stages, cells display
a loss of cell volume with few or no changes in the integrity and structure of cellular
organelles (including the plasma membrane), and chromatin condensation (23). In the
later stages of apoptosis, cells shrink, and display membrane blebbing and DNA
fragmentation.

In addition, apoptotic cells expose phosphatidylserine and display

changes in membrane permeability (6). However, it is worth noting that any given
group of cells tends to exhibit asynchronous death, and that no one death mechanism
needs to display all the features listed above in order to fit the definition (23).
Autophagy, a second type of PCD, should more precisely be named “PCD with
autophagy,” as the process in and of itself does not necessarily cause death. Cells
undergoing autophagy display degenerate organelles, but generally do not display
chromatin condensation (23). Autophagy involves the formation of an autophagosome,
a double membrane bound compartment that forms de novo in the cytoplasm, fuses
with the lysosome, and allows for the degradation of its contents along with its inner
membrane (24). It was once believed to serve as a mechanism to conserve and recycle
cellular components in response to stresses such as nutrient limitation; now, it is
understood that autophagy plays a constitutive role in the destruction of extra or
damaged organelles, and it can be involved in the destruction of invading intracellular
microbes (24).
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Regardless of the terminology used, processes such as apoptosis play an
important role in the survival of multicellular organisms. For example, apoptosis is
required for developmental processes, homeostasis of tissues, protection from
microbial invasion, and prevention of cancer; apoptosis causes cell death without
triggering the cascade of inflammation (6).

Interestingly, it is now accepted that

unicellular organisms also undergo an apoptosis-like cell death, although the details
involved in the process have not been identified (6).
Single-celled eukaryotes and PCD: apoptosis and autophagy
PCD has recently been described for single-celled eukaryotes, including, but not
limited to, Dictyostelium, Trypanasoma, Leishmania, Giardia, Trichimonas, and
Plasmodium (reviewed in (6)). In these model organisms, PCD can be induced by
reactive oxygen species, drugs, heat shock, starvation, and high density, among other
stimuli (6).

Some have speculated that populations of unicellular organisms

communicate and organize themselves in ways that might resemble the cells of
multicellular organisms. From the point of view of a unicellular parasite, evolutionary
pressure is felt by each of the members of the population. Typically, the population is
often founded by one or few individuals; therefore, the death of a single organism
would not prevent the propogation of its genetic material. PCD may be employed to
limit the untimely killing of the host due to large numbers of parasites, or may limit the
immune response by the host (6).
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PCD has been observed in E. histolytica. In one study, it was observed that E.
histolytica undergoes apoptosis in vitro in response to nitric oxide species (31). The
authors used DNA fragmentation, YOPRO-1 staining, and TUNEL assays to demonstrate
the apoptotic-like morphology of cell death. Although some metabolic changes were
observed (ATP levels were reduced), the authors proposed no specific mechanism for
cell death (31). The antibiotic G418 has also been shown to induce a PCD phenotype in
E. histolytica. In this case, the authors demonstrated that G418 reduced cell size,
induced DNA fragmentation, and caused increases in cytosolic calcium levels (39).
Once again, a specific mechanism was not proposed, although an in silico search of the
E. histolytica genome found no putative caspase proteins (39).

Therefore, it is likely

that if the parasite indeed undergoes an apoptotic program of cell death, it is unrelated
to the commonly studied mammalian pathways.

Although the notion that PCD

pathways in single-celled eukaryotes may be different from that of mammalian systems
makes their study more difficult, proteins in these pathways may represent unique drug
targets.
Among unicellular parasites, most of the known apoptotic machinery is missing,
yet many autophagy molecular markers are present, such as TOR kinase and Atg8 (6).
While the exact molecular mechanisms involved in the formation of autophagosomes
and cargo selection are not well understood in any eukaryotic cells, it is known that
autophagy can be regulated by numerous signals, including hormones and growth
factors (24). The genes involved in the autophagy pathway are known as ATG genes, and
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the “core” ATG genes are those required for the formation of the membranes required
for autophagy. ATG8 associates with the isolation membranes (an autophagosomal
precursor) and autophagosomes, and is considered to be a universal marker for
autophagosomal membrane dynamics in all eukaryotic cells (24).
Interestingly, studies in Saccharomyces cerevisiae have demonstrated that the
formation of particular protein complexes is important for the proper function of
autophagy pathways. In particular, VPS34, the lone PI3-kinase (PI3K) in yeast, associates
with two separate complexes, which differ by only one subunit. (For a review of PI3Ks,
see Part III.) Depending on the subunit that associates with VPS34, a different complex
forms, each of which differentially regulates the autophagy pathway (24). E. histolytica
possesses some of the known autophagy machinery. Picazarri, et al. performed a search
of the E. histolytica genome, and identified the genes for only one of the two autophagy
regulation systems, known as the Atg8 conjugation system. Similar genes were found in
two other Entamoeba species, E. dispar and E. invadens. However, as in Dictyostelium
discoideum, the Atg5-to-Atg12 system is missing in E. histolytica (27).
The role of autophagy in development is relatively well-studied in lower
eukaryotes. For example, inhibition of Atg genes in C. elegans prevented development
past a particular stage, and Dictyostelium discoideum mutants lacking Atg5 or Atg7 were
defective in the spore-forming period of the developmental life cycle (27). While E.
histolytica does not have a developmental life cycle per se, it does transition from
trophozoite to cyst forms; studies that involve encystation must be carried out in the
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related reptilian parasite, E. invadens, because E. histolytica does not encyst in culture
(27). In order to investigate the involvement of autophagy in E. invadens encystation,
Picazarri et al. used an antibody generated against EhAtg8 to demonstrate that EhAtg8
levels changed over time in culture. Specifically, the percentage of cells with Atg8positive structures increased during encystation, and furthermore, the subset of Atg8positive cells had even more Atg8-positive structures after 24 hours into the encystation
process (27). Perhaps most importantly, the authors demonstrated that wortmannin, a
PI3K inhibitor, inhibited the formation of Atg8-positive structures, suggesting a role for
PI3Ks in E. histolytica autophagy, as in yeast (27).
As mentioned, several stimuli induce PCD in single-celled organisms.

Of

particular interest is the observation that MTZ induces PCD in the protozoan parasite
Blastocystis hominis (25). In response to MTZ exposure, the parasite exhibited nuclear
condensation, nicked DNA, and reduced cytoplasmic volume (25). Unlike E. histolytica,
PCD in B. hominis may be associated with a caspase cascade (25). While the two
parasites may utilize different PCD mechanisms, it is interesting that MTZ can induce
PCD in a protozoan parasite. Although the authors did not specify if the type of PCD
observed was apoptosis or autophagy, it is possible that MTZ might induce autophagy.
Recall, MTZ binds DNA and causes irreversible damage. Katayama et al. tested
the effects of drugs known to damage DNA, temozolomide (TMZ) and etoposide, on
autophagy in a malignant glioma cell line (18). TMZ is believed to cause DNA damage by
causing thymine mismatching during DNA replication, and it is known that DNA damage
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in these cells does not induce apoptosis (18). The researchers found that the DNA
damaging drugs caused increased ATP production (one mechanism of enhanced cell
survival caused by activation of the autophagy pathway), and this ATP production was
blocked by pre-incubation with 3-methyladenine (an autophagy inhibitor) or by using
shRNA to silence beclin 1 (the protein product of which is required for autophagosome
formation) (18). Therefore, drugs that induce DNA damage might induce autophagy.
Since autophagy may play a role in degrading damaged organelles, it is possible that this
may be a self-protection mechanism utilized by cells exposed to drugs, and this may be
a mechanism of drug resistance (18).

III. Phosphoinositide-based signaling
Regulation by second messenger lipids
In order to regulate cell signaling pathways, including those related to processes
such as PCD, proteins must be recruited to the site of signal transduction, which is often
the plasma membrane.

The activation of such effector proteins must be tightly

regulated, both in space and in time (13). Regulation is often accomplished by the
interaction of signaling proteins with lipids at the site of the plasma membrane or within
specific membrane compartments (20).

Upon recruitment and activation of effector

proteins, several local and global effects on the cell can be observed. For example, lipids
or proteins can be phosphorylated by kinases. Alternatively, second messengers, which
amplify the signal cascade, may be generated. If the signal cascade relates to vesicle
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trafficking, the plasma membrane and/or cytoskeleton may be remodeled (13).
Typically, signal transduction cascades involve a combination of these scenarios.
Because regulation of signal transduction can be accomplished by interactions
with membrane lipids, many signaling proteins contain lipid binding domains, which
commonly interact with acidic phospholipids such as phosphatidylserine, phosphatidic
acid, and phosphatidylinositol (PI). Small subclasses of PIs are phosphorylated, and are
known as phosphoinositides. These phosphorylated lipids interact with proteins (20),
and these lipid species are rare compared to other phospholipids; for example, in
mammalian cells, phosphatidylinositol bisphosphate (PIP2) makes up no more than 1%
of the plasma membrane inner leaflet, compared to phosphatidylserine, which can
account for up to 35% (20). Typically, positively charged amino acid residues on
proteins specifically interact with anionic phosphoinositide species.
Because the activity and location of kinases (enzymes which add phosphates)
and phosphatases (enzymes which remove phosphates) involved in the generation of
various phosphoinositide species are regulated by signaling cascades, there is also tight
regulation of any given phosphoinositide species, making those lipids an integral part of
cell signaling regulation (13). Phosphoinositides are involved in signaling pathways that
alter membrane trafficking, cytoskeletal changes, cell movement, cell survival, and
immune regulation. Therefore, studying their role in cells is critical for understanding
multiple realms of cell biology.
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Proteins with lipid binding domains
Despite the importance of understanding the role of phosphoinositides in cell
signaling, their rapid turnover rates prevent study by traditional biochemical methods.
It has become common practice to use fluorescently-tagged phosphoinositide protein
binding domains and live cell imaging to study the location and dynamics of these lipids
during cellular events (13). There are several families of protein domains that bind
phospholipids, some of which bind very specifically (PHBtk and PHPKB/Akt bind PI(3,4,5)P3,
FYVEEEA1 and FYVEHrs bind PI3P, and PHPLCδ1 binds PI(4,5)P2), and some of which bind
promiscuously (various C2 domains bind phosphatidylserine, anionic phospholipids,
zwitterionic phospholipids, and possibly PI) (13, 20).
Although the involvement of these lipids has been extensively studied in
mammalian cells, it is still unclear whether these lipids are involved in similar signaling
cascades in single-celled eukaryotic cells. For example, PI3P localization was studied in E.
histolytica using a lipid binding protein biosensor: two FYVE domains were linked and
tagged with GST. This study demonstrated that in E. histolytica, PI3P was localized to
endosomes carrying specific cargo; fluid phase pinosomes showed no enrichment of
PI3P, but newly forming and newly sealed phagosomes harboring human erythrocytes
or bacteria were enriched in this lipid (29). This was in contrast to macrophages, in
which PI3P was only detected after phagosomes had sealed (38).
More recently, a similar study was undertaken, which utilized both a GST- and a
GFP-labelled PHBTK domain to study the localization and dynamics of PIP3 in E. histolytica
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endocytosis (7). In this case, labeling of PIP3 with a GST-PHBTK bioprobe revealed that
PIP3 levels existed in a high steady state, and that PIP3 was concentrated at the
periphery of the cells under normal culture conditions as well as during serum
starvation (a condition that presumably reduces cell signaling). Furthermore, PIP3 was
not associated with fluid-filled endosomes, but was localized to the periphery of newly
forming erythrophagosomes (7).

In addition, live cell imaging, using a cell line

expressing GFP-PHBTK, supported these results. When E. histolytica was engulfing a
human erythrocyte, the PIP3 pool was depleted from the membrane and localized to the
phagosome. E. histolytica cells expressing GFP-PHBTK were rarely observed engulfing
erythrocytes; therefore, endocytosis was measured in this cell line. It was observed that
expression of GFP-PHBTK caused inhibition of phagocytosis, but not pinocytosis, in E.
histolytica (7).
Others have observed that expression of lipid binding domains in other cell
types, including the PHBTK domain, caused this “dominant negative” phenotype. One
hypothesis is that the binding of the artificially expressed PH domain to PIP3 prevents
the binding of physiologically relevant proteins, including those that may be involved in
signaling cascades which facilitate phagocytosis and/or cytoskeletal remodeling (Fig.
1.3). In this scenario, signaling events downstream of PIP3 are inhibited. Since PIP3 is
one of the products of PI3K, it is hypothesized that this E. histolytica cell line (GFP-PHBTK)
represents a PI3K dominant negative mutant cell line. This is important, because it
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Figure 1.3. Signaling pathways involving PI3Ks.
A. Upon activation of particular signal cascades, PI3K phosphorylates PIP2, resulting in
the formation of PIP3. Then, effector proteins, such as Akt, can bind to PIP3 via a lipid
binding domain, in this case, a PH domain. In mammalian cells, activation of Akt leads
to downstream effects, which can activate pathways involved in cell growth,
proliferation, and survival. B. When PH domains (such as GFP-PHBtk) are expressed
artificially in a cell line, it is believed that their binding to PIP3 may prevent the binding
of physiologically relevant effector proteins, such as Akt. In the absence of such binding,
signal cascades that depend on these effector proteins may not be activated properly.
In this example, signals that promote cell survival, growth, and proliferation may be
missing.
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allows for the study of events that may depend on the activity of PI3K without using
chemical inhibitors of the enzyme, such as LY294002 and wortmannin.
It is important to note that in mammalian systems, the idea that proteins
downstream of PIP3 are not properly activated has been substantiated using antibodies
to such proteins, one of which is Akt. Upon activation, proteins such as Akt are
phosphorylated, and western blots using commercially available antibodies to the
unphosphorylated vs. phosphorylated versions of these proteins have provided insight
into the activation state of this downstream signaling protein. Our attempt to use
antibodies to Akt and phospho-Akt in E. histolytica proved unsuccessful (data not
shown); therefore, the notion that this cell line is behaving as a PI3K dominant negative
“mutant” is purely correlated with the reduced levels of erythrophagocytosis (7), a
vesicle trafficking pathway that is likely dependent on PI3K signaling (29, 35, 38).

IV. Summary
Although the statistics enumerating the number of infections caused by E.
histolytica may be outdated, it is clear that the impact of amoebiasis on global health is
great. Given that diarrheal diseases kill over two million people each year and that
more than one billion people have no access to clean water, it is unlikely that the
disease burden will be reduced in the near future. In addition, while the progress being
made toward a vaccine is noteworthy, the fact remains that treatment will likely involve
the use MTZ for the immediate future. Therefore, understanding the cell biology
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involved in disease progression and understanding the potential for drug resistance is
necessary for treating E. histolytica infections.
The goal of this thesis project is to investigate the potential role of PI3K signaling
pathways in drug susceptibility in E. histolytica. The specific hypothesis is that cells that
exhibit reduced or limited PI3K signaling may be missing key “survival” signals; such a
lack of signal transduction events may make these cells more susceptible to DNA
damaging drugs such as MTZ. Therefore the specific objectives of this study are:
1. To determine if genetic and/or chemical inhibition of PI3Ks increases the MTZsusceptibility of E. histolytica cells.
2. To determine if MTZ induces PCD in E. histolytica.
3. To determine what role (if any) PI3Ks play in PCD in E. histolytica.
To our knowledge, this is the first report that provides evidence that PI3Ks indeed play a
role in MTZ resistance in any cell type, and the first report that demonstrates that MTZ
can induce PCD in E. histolytica.
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CHAPTER TWO
INHIBITION OF PI 3-KINASE SIGNALING CONTRIBUTES TO METRONIDAZOLE RESISTANCE
IN THE PROTOZOAN PARASITE, ENTAMOEBA HISTOLYTICA

I. ABSTRACT
Entamoeba histolytica is a protozoan parasite that causes amoebic dysentery
and liver abscess, and contributes to the two million worldwide deaths caused by
diarrheal diseases. Current treatments for amoebiasis include the use of the DNA
damaging drug, metronidazole (MTZ), and fortunately, drug resistance has not been a
problem to date. However, an E. histolytica laboratory-generated cell line, which
expresses a GFP-labeled pleckstrin homology (PH) domain (derived from mammalian
Bruton’s tyrosine kinase, PHBTK), exhibited increased resistance to MTZ.

PHBTK

specifically binds phosphatidylinositol (3,4,5)-trisphosphate (PIP3), a major product of
PI3-kinase (PI3K) activity, and expression of GFP-PHBTK can result in the inhibition of PIP3based signaling and a PI3K dominant-negative phenotype. To test the involvement of
PI3Ks in MTZ resistance, wildtype cells were incubated with a PI3K inhibitor, followed by
incubation with MTZ. Cell killing was assessed and the drug resistance phenotype of the
GFP-PHBTK cell line was recapitulated. To better understand the resistance mechanism
in cells expressing GFP-PHBTK, we first explored the effects of MTZ on wildtype cells. We
incubated wildtype cells with MTZ, and observed phenotypes associated with
programmed cell death, including changes in the appearance of the nucleus, and cell
shrinkage. Surprisingly, MTZ also induced these changes in cells expressing GFP-PHBTK.
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Together, these data suggest that MTZ may kill E. histolytica cells in a PI3K signaldependent manner, and may induce a program of cell death in E. histolytica.
Importantly, these data suggest that subtle changes in signaling pathways in the
pathogen could result in MTZ-resistant strains of E. histolytica.

II. INTRODUCTION
Amoebiasis is caused by the protozoan parasite, Entamoeba histolytica (45),
which is one of the infectious organisms that contributes to the estimated two million
deaths per year caused by diarrheal diseases (17, 46). The amoeba is distributed
worldwide; however, a high prevalence of infections is seen in countries where a lack of
sanitation allows its fecal-oral spread (47). For example, in Bangladesh, approximately
39% of pre-school age children are infected with the parasite (23). Disease severity can
vary from amoebic colitis to more invasive disease, which is characterized by abdominal
pain, bloody diarrhea, or abscesses in the liver or the brain (29). Those at risk for the
most severe disease states include the very young, the very old, and the malnourished
(29); deaths caused by diarrheal diseases usually occur in children under five (17).
Because of a lack of improvement in sanitation and because there is currently no
vaccine for E. histolytica (14), symptomatic patients are commonly treated with
amoebicidal drugs in the nitroimidazole family, such as metronidazole (MTZ) (45).
Fortunately, little clinical resistance to MTZ by E. histolytica has been observed
(3-5). However, for infections with Giardia, the prevalence of clinical MTZ resistance has
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been reported to be as high as 20% (36). In addition, MTZ resistance in Trichomonas
vaginalis was first reported in 1962 (36). Interestingly, MTZ is active only when it is
reduced by the metabolic activities of the target cell (34). After activation, MTZ binds to
DNA and proteins, causing irreversible damage (32). It is believed that
pyruvate:ferredoxin oxidoreductase (PFOR), an iron-sulfur protein involved in
fermentation pathways, reduces ferredoxin (Fdx), which, in turn, reduces and activates
MTZ (32).

Most higher eukaryotic cells lack PFOR, preventing activation and cell

damage. Although it has been reported that MTZ resistant Giardia exhibits reduced
PFOR activity and MTZ resistant trichimonads display reduced expression of Fdx, some
researchers have suggested that E. histolytica has no metabolic alternates to the
PFOR/Fdx pathway (32). Because E. histolytica probably cannot modify enzyme levels to
avoid activating MTZ (as Giardia and Trichimonas can), it has been postulated that this
may explain the lack of clinical MTZ resistance in E. histolytica (32).
In addition to resistance mechanisms that alter metabolic activation of drugs,
protozoan parasites and other eukaryotic cells (13) sometimes utilize ATP-binding
cassette (ABC) pumps, also known as multidrug resistance (MDR) pumps or Pglycoprotein (Pgp) pumps, to extrude drugs from the cell. A recent RT-PCR based study
of clinical isolates of E. histolytica in India found no overexpression of EhPgp1 (5), a gene
encoding one of four expressed Pgp pumps in the amoeba (11). However, it has been
hypothesized that MTZ may not be a substrate of such pumps (33). Therefore, studies
such as these may not fully represent the potential for clinical MTZ resistance by E.
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histolytica.

Furthermore, Pal et al. recently reported that E. histolytica possesses

nitroimidizaole reductase genes, which are capable of conferring MTZ resistance to
transformed bacteria (26). In addition, step-wise increases in MTZ exposure have
resulted in the induction of resistance in two axenic laboratory strains of E. histolytica,
HM-1:IMSS (41) and HTH-56:MUTM (36), emphasizing the idea that MTZ resistance is
possible in E. histolytica.

Clearly, there is an incomplete understanding of MTZ

resistance mechanisms in the parasite.
As mentioned above, activated MTZ causes irreversible damage to DNA and
proteins.

Recently, it was demonstrated that MTZ induces an apoptotic-like

programmed cell death (PCD) program in the protozoan parasite, Blastocystis hominis
(24).

Several recent reports have demonstrated that single-celled organisms can

undergo PCD. For example, both G418 (40) and reactive nitrogen species (31) have
been implicated in the induction of PCD programs in E. histolytica. The signaling
cascades involved in PCD in single-celled eukaryotes have not been studied extensively
(7). However, PI3 kinase-(PI3K)-based signaling is commonly involved in anti-apoptotic
signal cascades in mammalian cells (20).
Recently, an E. histolytica cell line which overexpressed a GFP-labeled pleckstrin
homology (PH) domain of Bruton’s tyrosine kinase (GFP-PHBTK) was developed and
characterized (8). This cell line displayed reduced phagocytosis, a vesicle trafficking
process which relies on PI3K-based signaling cascades in other cell types (8). This
suggests that PI3K signaling pathways are inhibited in this cell line. Other researchers
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observed similar PI3K “dominant-negative” phenotypes after overexpression of PH
domains (37). It has been hypothesized that exogenous PH domain peptide fragments
might disrupt PI3K signaling by binding and sequestering lipids or proteins involved in
the propagation of the physiologically relevant signal cascade.
Given the potential connection between PI3Ks and cellular survival signals, and
given that MTZ can induce PCD in another protozoan parasite, we investigated whether
disruption of PI3K signaling could alter susceptibility to MTZ. We hypothesized that
since MTZ causes DNA and protein damage and can induce apoptosis, and since cells
expressing GFP-PHBTK may lack the ability to propagate cell survival signals via the PI3K
pathway, this cell line might be more susceptible to MTZ-induced killing as compared to
wildtype (WT) cells.
To test this, we characterized MTZ sensitivity in WT cells, cells expressing GFPPHBTK, and in cells expressing other exogenous proteins. Intriguingly, our results did not
support our initial hypothesis. The cell line expressing GFP-PHBTK was more resistant to
MTZ killing as compared to WT cells or other mutant cell lines we tested, suggesting a
connection between PI3K signaling and MTZ sensitivity. We also tested mechanisms
known to be involved in resistance to MTZ and other drugs. We found that PI3K-related
MTZ resistance was not due to a general MDR phenotype, as measured by an MDR
assay kit, nor was it associated with increased levels of superoxide dismutase (SOD), a
characteristic of a MTZ-resistant E. histolytica laboratory strain (41). However, we found
that MTZ caused changes in WT cells reminiscent of the PCD phenotype described in
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other single celled eukaryotes, including cell shrinkage and changes in the appearance
of the nucleus. MTZ induced similar changes in E. histolytica cells expressing GFP-PHBTK.
While we have not yet determined how inhibition of PI3K signaling protected cells from
MTZ killing, this is the first report describing a role for PI3K signaling in MTZ resistance
and the first report describing the MTZ-induced program of PCD in E. histolytica. Studies
to further characterize the connection between PI3K signaling and MTZ-induced PCD in
E. histolytica are currently underway.

III. MATERIALS AND METHODS
Strains, culture and assay conditions
E. histolytica cells (strain HM-1:IMSS) were axenically grown at 37°C in 15 mL glass
screw cap tubes in TYI-S-33 media (12). Assays were performed in serum free media
(TYI-33). E. histolytica cell lines expressing EhRabA-Q84L (44) and GFP and GFP-PHBTK (8)
are described elsewhere (Also see Appendix B); each mutant cell line was maintained
with the addition of 6 µg/mL G418 and 15 µg/mL hygromycin to the culture medium.
Prior to using these cell lines for experiments, exogenous expression of mutant proteins
was induced by the addition of 5 µg/mL tetracycline to the culture medium for 24 hours
as previously described (30).
Treatments with MTZ
MTZ-induced killing was measured using vital dye staining and cell counting assays. WT
or mutant cells were incubated in 70 µg/mL MTZ (IC50) for 4 hours at 37°C. In some
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assays, WT cells were pre-treated with the PI3K inhibitor, LY294002 (40 µM) (28) or its
diluent control (ethanol), or the LY294002 negative control analog, LY303511 (40 µM) or
its diluent control (DMSO), for 15 min at 37°C. In these assays, additional inhibitor was
added to the cells during MTZ treatment in order to keep the drug concentration
constant throughout the 4 hour MTZ exposure. Cells were then stained with the vital
dye, trypan blue (0.2% (v/v) final concentration). Viability was determined by counting
the number of live and dead cells using an Olympus CK2 light microscope. At least 2 sets
of 100 cells each were counted during each trial. The data represents the mean of at
least 3 trials +/- SD.
MDR assays
Resistance caused by MDR pumps was quantified using the VybrantTM MDR Assay Kit
(Invitrogen, Carlsbad, CA), with modifications to the manufacturer’s protocol. Tubes of
WT and mutant cells were chilled on ice for 10 minutes to release trophozoites from the
glass, centrifuged at 500 x g for 5 min and washed twice in room temperature (RT) PBS.
Next, 5 x 105 cells were pre-treated with 10 µg/mL verapamil (33), a MDR pump
inhibitor, or an equivalent volume of diluent control (ethanol) at 37°C for 15 min. Then,
cells were incubated with calcein AM (250 nM) at 37°C for 15 min. Cells were washed
once in ice cold media, twice in ice cold PBS, and resuspended in ice cold PBS. Cell
suspensions were pipeted into the wells of a 96 well plate and fluorescence was
measured using a microplate fluorescence reader (BioTek, Winooski, VT) at an excitation
wavelength of 485 nM and emission wavelength of 528 nM. Each treatment was
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performed in duplicate and the fluorescence values were averaged. Because some of
the cell lines expressed GFP, the fluorescence of each untreated cell line was set at
100%, and the fluorescence of the cells after verapamil treatment was reported as a
percentage of the corresponding untreated control fluorescence.
Western Blot Analysis
Tubes of E. histolytica cells were chilled on ice to release the trophozoites from the
glass.

The amoebae were centrifuged and washed twice in PBS.

Cells were

resuspended in LDS sample buffer (supplemented with 10% β-mercaptoethanol) and
western blots were performed as described (43). Anti-Mn SOD polyclonal antibody was
obtained from Assay Designs-Stressgen (Ann Arbor, MI). Use of the antibody in E.
histolytica was first validated by incubating WT lysates with different dilutions of the
antibody (1:1000, 1:500) and by incubating increasing lysate concentrations (0.5 x 105, 1
x 105, 2 x 105 cells/lane) with the antibody.
Microscopy
WT E. histolytica trophozoites were incubated in 15 mL screw cap tubes at 37°C in TYI-S33 supplemented with 70 µg/mL MTZ or an equivalent volume of PBS (diluent control)
for up to 18 hours. E. histolytica cells harboring GFP-PHBTK were incubated for 24 hours
with tetracycline to induce the expression of the protein, and were then incubated up to
an additional 18 hours in PBS or MTZ as described above. Cells were then chilled on ice
to remove them from the glass, centrifuged at 500 x g, and washed twice in PBS to
remove the autofluorescent media and the drug. Each pellet was resuspended in a
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mixture of PBS, Hoescht stain (100 µg/mL final concentration), and propidium iodide (20
µg/mL final concentration), and the cells and staining mixture were incubated at 37°C
for 20 minutes as described (38). An aliquot of stained cells plus additional PBS was
then pipeted into the wells of a LabTek coverglass chamber. Live cells were imaged
using a Nikon Eclipse Ti microscope and image analysis, including calculation of cell
surface area, was conducted using Nikon NIS Elements software. The cell size data
represents at least three trials; in each trial, size data from approximately 100 cells was
recorded and averaged. Images of stained cells represent at least two trials.
Statistical Analyses
All values represent the average of the results of at least three trials (+/- standard
deviations). Statistical analyses were performed using GraphPad Instat V.3. Data was
analyzed using either a Welch-corrected unpaired t-test or a one way ANOVA with the
Tukey multiple comparisons test. P values less than 0.05 were considered statistically
significant (*), while P values less than 0.01 (**) or less than 0.001 (***) were
considered highly statistically significant.

IV. RESULTS
E. histolytica cells expressing GFP-PHBTK are resistant to MTZ
After incubation with MTZ, approximately 50% of WT cells were killed. However, less
than 30% of cells expressing GFP-PHBTK were killed after MTZ incubation (Fig. 2.1),
suggesting PI3Ks may play a role in MTZ resistance in E. histolytica. As a control, we also
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examined cells expressing GFP or cells overexpressing a GTP-bound version of EhRabA
(EhRabA-Q84L). In these cell lines, MTZ induced cell death that was comparable to WT
cells (Fig. 2.1), suggesting that the resistance observed in cells expressing GFP-PHBTK was
specific.
LY294002, a PI3K inhibitor, induces MTZ resistance in WT E. histolytica
In order to further assess the role of PI3Ks in MTZ resistance in E. histolytica, WT cells
were pre-treated with the PI3K inhibitor, LY294002, or a negative control analog,
LY303511. Cells were then incubated in MTZ (plus additional inhibitor) for 4 hours and
cell viability was assessed by trypan blue exclusion and cell counting. Cells incubated
only with LY294002, LY303511, or diluent controls (ethanol or DMSO, respectively) were
not killed during the 4 hour incubation time (Figs. 2.2A, 2.2B). However, approximately
50% of the cells incubated in MTZ alone were killed (Figs. 2.2A, 2.2B). Interestingly, like
GFP-PHBTK cells, which are proposed to have a PI3K signaling defect, WT cells treated
with the PI3K inhibitor, LY294002, were protected from MTZ-induced killing (~37%
death) (Fig. 2.2A). However, cells treated with a LY294002 negative control analog,
LY303511, which does not inhibit PI3Ks, were not protected from MTZ-induced killing
(~50% death) (Fig. 2.2B).
Multiple E. histolytica mutant cell lines exhibit a MDR phenotype
Because it has been reported that MDR is a mechanism of drug resistance in cancer cells
(13), Leishmania and Plasmodium (6), and E. histolytica (25), we tested the MDR
phenotype in each cell line that had been exposed to MTZ. As compared to WT cells,
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Figure 2.1. MTZ kills E. histolytica cell lines expressing different exogenous proteins
with varying efficiencies.
WT and mutant cell lines were exposed to 70 µg/mL MTZ for 4 hours at 37°C, and cell
viability was determined using trypan blue exclusion and cell counting. After 4 hours in
MTZ, approximately 50% of WT cells, 40% of cells expressing GFP, and 55% of cells
expressing a constitutively active version of EhRabA (EhRabA-Q84L) were killed.
However, less than 30% of cells expressing GFP-PHBTK were killed; this was significantly
less cell death as compared to WT cells (P < 0.01, **).
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Figure 2.2. The PI3K inhibitor, LY294002, specifically induces MTZ resistance in WT
cells.
(A) WT cells were pre-incubated with (+) LY294002 or with diluent control (-, X) for 15
min, followed by incubation in MTZ (+) or diluent control (-, PBS), plus additional
LY294002 and/or diluent control, for 4 hours at 37°C. Approximately 5% of cells
incubated only in diluent controls or in LY294002 alone were killed. As expected,
approximately 50% of cells incubated only in MTZ were killed. However, significantly
fewer cells (35%) incubated with LY294002 and MTZ were killed (**, P < 0.01). (B) The
experiment described in (A) was repeated, using LY303511, an analog to LY294002 that
does not inhibit PI3Ks, and its diluent control. In this case, approximately 10% of WT
cells incubated in diluent controls or LY303511 were killed, and approximately 50% of
cells incubated in MTZ (with or without the LY analog) were killed.
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three mutant cell lines exhibited drug resistance in a calcein AM based assay. Calcein
AM is a non-fluorescent dye, and a known substrate of MDR pumps. After diffusing
across cell membranes, cellular esterases cleave calcein AM, preventing its diffusion and
release across the cell membrane, and allowing it to fluoresce.

Cells that are

overexpressing pumps or have overactive pumps in the membrane retain less
fluorescence due to the initial exclusion of the calcein AM dye. As demonstrated in Fig.
2.3, cells expressing GFP-PHBTK (Fig. 2.3A), GFP (Fig. 2.3B), or a constitutively GTP-bound
form of EhRabA (EhRabA-Q84L) (Fig. 2.3C), exhibited significantly less staining with
calcein AM, suggesting that each cell line excludes the dye, presumably via MDR pumps.
To test this, WT cells and each mutant cell line were also treated with verapamil, a
calcium channel blocker that inhibits MDR pumps, prior to incubation with calcein AM.
While WT cells exhibited minimal differences in calcein AM staining with or without
verapamil treatment, each mutant cell line exhibited statistically significant differences
in staining after verapamil treatment (Fig. 2.3). Presumably, blockage of active MDR
pumps by verapamil treatment allowed the cells to acquire the calcein AM stain.
Additionally, after verapamil treatment, there were no statistically significant
differences in the mutant cell lines as compared to WT cells. Since E. histolytica cell
lines expressing different exogenous proteins exhibited MDR, but only cells expressing
GFP-PHBTK were resistant to MTZ, it is unlikely that MDR is responsible for its MTZ
resistant phenotype. Therefore, we explored other known MTZ resistance mechanisms.
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Figure 2.3. Several E. histolytica cell
lines display a moderate MDR
phenotype.
WT cells or cells expressing GFPPHBTK (A), GFP (B), or EhRabA-Q84L
(C) were exposed to verapamil (+)
or diluent control (ethanol, -),
followed by incubation with the
fluorescent stain, calcein AM.
Fluorescence (excitation 485 nm,
emission 528 nm) was measured
using a plate reader. In each case,
the fluorescence of the tested cell
lines incubated without verapamil
was reported as 100%, and the
fluorescence of the cells after
verapamil treatment was reported
as a percentage of the untreated
cell fluorescence. In each set of
experiments, minor (A, *, P < 0.05)
or no significant (B, C) changes were
observed in WT fluorescence before
or after verapamil treatment,
suggesting little or no activity of
MDR pumps in WT cells. However,
all 3 mutant cell lines displayed a
significant change in fluorescence
after verapamil treatment (A, ***, P
< 0.001; B, **, P < 0.01; C, ***),
suggesting that exposure to small
molecules,
including
G418,
hygromycin, and/or tetracycline
may increase the baseline activity of
MDR pumps in E. histolytica.
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Baseline levels of SOD in the cell lines
It has been reported that laboratory strains of MTZ-resistant E. histolytica exhibit
increased levels of SOD (41). In order to determine if cells expressing GFP-PHBTK were
better able to detoxify reactive oxygen species generated by MTZ exposure, levels of
SOD were assessed by western blot techniques. We used a commercially available
antibody to SOD, which has not been described for use in E. histolytica. Therefore, we
first validated the utility of the antibody. We conducted western blot analysis on a
range of concentrations of cell lysates using two different antibody concentrations (Fig.
2.4A). Indeed, we observed a “dose-dependent” relationship in the intensity of bands
observed by western blot. Importantly, the upper band of the observed doublet was
approximately 25 kDa, the published size of E. histolytica SOD (41). Next, we collected
WT cells and cells induced to express GFP or GFP-PHBTK. Cells were counted, lysates
were prepared as described (43), and western blots using α-SOD antibodies were
performed. Each cell line appeared to have approximately equal baseline levels of SOD.
However, a second smaller band was observed in the “wildtype” lane, which was not
prominent in the “GFP” or “GFP-PHBTK” lane. In addition to counting cells prior to
subjecting the lysates to western blot analysis, silver stains were performed separately
on each sample to confirm equal loading (data not shown).
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MTZ can induce a PCD-like phenotype in E. histolytica WT cells and
cells expressing GFP-PHBTK
In order to assess the possibility that MTZ resistance in GFP-PHBTK cells is related to a
program of cell death, we first needed to investigate whether or not MTZ could induce
phenotypic characteristics of PCD in WT E. histolytica, as it can in B. hominis. We
utilized two nuclear stains: Hoescht and propidium iodide (PI). Hoescht crosses the
plasma membrane and nuclear envelope of live or dead cells, while PI crosses only the
membranes of dead or dying cells. Therefore, the combination of these two stains has
been used to identify necrotic cells and apoptotic cells. The nuclei of necrotic cells are
stained primarily with PI and appear red, the nuclei of cells in “early” apoptosis are
stained predominantly with Hoescht and appear blue, and the nuclei of cells in late
apoptosis often appear pink or purple, as they may be doubly stained (38). Indeed, after
four hours of incubation in MTZ, no distinguishable changes in nuclear morphology were
observed by Hoescht staining (See Appendix D). However, changes after 18 hours were
quite prominent (Fig. 2.5). As compared to untreated (PBS, diluent control) cells, those
incubated with MTZ frequently contained a nucleus with unusual staining patterns. For
example, the DNA appeared web-like or was condensed. Moreover, prominent nuclear
membrane staining was often observed in these cells; this “halo” surrounding the
nuclear contents was not observed in the untreated cells. Also, cells treated with MTZ
had a blebbed appearance. Since MTZ induced morphological changes indicative of PCD
in WT cells, we expanded these experiments to include cells expressing GFP-PHBTK
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Figure 2.4. Western blot using anti-SOD antibodies.
(A) Untreated WT trophozoite lysates were incubated with α-SOD antibody diluted
1:1000 or 1:500 in TBS/Tween. Increasing lysate concentrations were exposed to the
antibody (0.5 x 105 cells/lane in lanes 1 and 4, 1 x 105 cells/lane in lanes 2 and 5, 2 x 105
cells/lane in lanes 3 and 6), and in each case, a doublet with an upper band
corresponding to the reported size of E. histolytica SOD (~25 kDa) was observed.
Importantly, the band intensity increased with cell number and with antibody
concentration, suggesting that binding was specific. (B) Baseline levels of SOD were
evaluated in WT, GFP, and GFP-PHBTK cell lines. Two bands were observed in the
“wildtype” lane. Each cell line possessed equivalent levels of the higher molecular
weight band.
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(Fig. 2.6). Like WT cells, the nuclei of cells expressing GFP-PHBTK, which had been treated
with MTZ, exhibited altered morphology.

The nuclei were frequently webbed in

appearance, and were often surrounded by a Hoescht-stained “halo” (Fig. 2.6).
In addition to the changes in nuclear and cellular morphology, we also observed
that both WT cells and cells expressing GFP-PHBTK were significantly smaller in surface
area after 18 hours of MTZ exposure (Fig. 2.7). Remarkably, the effect of MTZ was
nearly identical on the two cell lines: both MTZ-treated (+) WT cells and cells expressing
GFP-PHBTK were 45% of the size of the PBS control-treated (-) cell lines.
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Figure 2.5. WT E.
histolytica
cells
treated with MTZ for
18 hours displayed
changes
in
the
appearance of the
nucleus.
Cells were incubated
in (A) PBS (diluent
control) or (B) MTZ for
18 hours in glass tubes
at 37°C. Cells were
stained with Hoescht
and
representative
field images (Ai, Bi) or
images representing a
digital zoom of the
nuclear region (Aii, Bii)
are shown.
Cells
were co-stained with
propidium iodide (Aiii,
Biii). DIC (Aiv, Biv) and
merged images are
also shown. (C) After
18 hours of incubation
in
MTZ,
several
phenotypes
were
observed.
Nuclei
appeared
web-like
(Ciii), condensed (Ci),
or
displayed
a
combination of these
phenotypes with an
additional prominently
stained nuclear ring
(Ci, Cii, Ciii).
DIC
images are shown in
corresponding insets.
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Figure 2.6. E. histolytica cells expressing GFP-PHBTK treated with MTZ for 18 hours
displayed changes in the appearance of the nucleus.
Cells were incubated in PBS (A, B) or MTZ (C, D) for 18 hours in glass tubes at 37°C. Cells
were stained with Hoescht (i) and propidium iodide (ii). DIC images are also shown (iii).
After 18 hours of incubation in MTZ, nuclei were webbed in appearance and often
displayed a prominently stained nuclear ring. MTZ-treated cells also stained more
prominently with propidium iodide, suggesting that these cells have progressed to a late
stage of cell death.
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Figure 2.7. WT E. histolytica cells and cells expressing GFP-PHBTK were smaller in size
after 18 hours of MTZ exposure.
Diluent control-treated (PBS, -) WT or GFP-PHBTK cells were incubated in glass tubes at
37°C for 18 hours. Concurrently, WT cells or cells expressing GFP-PHBTK were incubated
with MTZ (+) under the same conditions. The surface area of approximately 100 cells
(N=4) was measured using Nikon NIS Elements software. The average size of diluent
control treated cells was set at 100%, and the average size of the MTZ-treated
corresponding cell line was reported as a percent of control. Remarkably, MTZ reduced
the average size of both cell lines to approximately 45% of the control cell size.
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V. DISCUSSION
In this study, we demonstrated that an E. histolytica cell line with a PI3Kdominant negative phenotype, GFP-PHBTK, was more resistant MTZ-induced killing as
compared to WT cells, cells expressing GFP, and cells expressing a GTP-bound Rab,
EhRabA-Q84L (Fig. 2.1). These results did not support our initial hypothesis that the
absence of cell survival signals induced by PI3K signaling might make cells expressing
GFP-PHBTK more susceptible to MTZ. The notion that inhibition of PI3K signaling was
indeed responsible for this change in MTZ resistance was supported by incubating WT
cells in the PI3K inhibitor, LY294002, and testing MTZ-induced killing (Fig. 2.2). WT cells
chemically inhibited in PI3K signaling were also statistically significantly more resistant
to MTZ as compared to diluent control-treated cells. Furthermore, MTZ resistance in
WT cells treated with a LY294002 analog, LY303511, a drug not believed to disrupt PI3K
signaling, was not altered (Fig. 2.2).
In order to investigate the mechanism of resistance in cells expressing GFP-PHBTK,
we tested established drug resistance mechanisms. We found that MTZ resistance in
this cell line was not related to MDR (Fig. 2.3), commonly responsible for drug resistance
in cancer cells (13), and some protozoans (6), nor was it related to increased expression
of SOD (Fig. 2.4), a characteristic of other laboratory-induced MTZ resistant E. histolytica
strains (41).

However, we demonstrated that MTZ was capable of inducing PCD

phenotypes in E. histolytica, like in B. hominis: after 18 hours of MTZ incubation, WT E.
histolytica cells and E. histolytica cells expressing GFP-PHBTK exhibited condensed and
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fragmented DNA as evidenced by Hoescht staining (Figs. 2.5 and 2.6) and reduced cell
size (Fig. 2.7). We considered the possibility that cells expressing GFP-PHBTK may be
protected from MTZ-induced PCD-like phenotypic changes because of reduced PI3K
signaling. Instead, cells expressing GFP-PHBTK appeared similar to WT cells under these
conditions (Figs. 2.6 and 2.7).
Our initial hypothesis was that E. histolytica cells expressing GFP-PHBTK and
lacking PI3K “survival” signals, might be less likely to overcome genetic insults caused by
a DNA damaging drug such as MTZ, and would be more susceptible to the drug.
However, we observed the opposite phenomenon: inhibition of PI3K signaling enhanced
MTZ resistance in E. histolytica. In mammalian systems, PI3Ks have an established role
in tumorigenesis (16).

PI3Ks phosphorylate PIP2, forming PIP3; PIP3 recruits and

activates Akt (a PH domain containing protein), which can then promote cell cycle
progression, inhibit apoptosis, and regulate protein synthesis and cell growth (16).
Because of this, PI3K signaling is highly regulated, and mammalian cells display low basal
levels of PIP3 (49). In contrast, single celled eukaryotic cells, including E. histolytica and
Dictyostelium discoideum, display relatively high steady-state levels of PIP3 (8, 49).
Others have speculated that these differences may be related to differences in
“lifestyle.” For example, E. histolytica relies heavily on phagocytosis for nutrient uptake;
given the proposed role of PIP3 in phagocytosis in these cells, high levels of PIP3 might
allow for constitutive phagocytosis (8). Also, unlike mammalian cells in which constant
PIP3 signaling might cause uncontrollable cell proliferation and tumor formation, E.
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histolytica cells are constantly and necessarily undergoing cell division (8) because they
are single-celled organisms.

Therefore, it is also feasible that “conventional” signal

cascades downstream of PIP3, seen in mammalian cells, may not operate identically in E.
histolytica. Perhaps the role of PI3Ks in cell survival is less important in cells that
seemingly possess high steady state levels of PIP3. Furthermore, at least one study has
demonstrated that the PI3K/Akt pathway can promote apoptosis mediated by Fas-FasL
(21). In this case, inhibition of PI3K, as in the GFP-PHBTK cells, might actually increase cell
survival signals. Studies such as these demonstrate that the context and mechanism of
cell death is important for understanding the potential role for PI3K-related signaling.
It is important, then, to address the mechanism of death induced by MTZ. The
long-standing paradigm of the mechanism of action is that MTZ is activated by a cell’s
metabolic activities. Specifically, it has been reported that PFOR reduces Fdx, which,
reduces NAD+ or MTZ to its active form (32). The nitro group of MTZ is reduced to a
nitroradical anion, which can be further reduced to a nitrosoimidazole (19), which then
binds to proteins and DNA, causing irreversible damage to the cell (32). However,
several recent studies have shown that like mammalian cells, single celled eukaryotes,
including D. discoideum and Giardia lamblia (7), Trypanasoma (42), and E. histolytica
(31, 40), undergo a program of cell death. PCD in these organisms can be induced by
stimuli such as starvation, reactive oxygen species, or drugs (7), including MTZ (7). A
2004 study demonstrated that MTZ induced PCD phenotypes such as cell shrinkage and
DNA fragmentation in the protozoan parasite, Blastocystis hominis (24). It now seems
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to be accepted that these organisms indeed undergo PCD; however, it is not wellunderstood whether the type of PCD is best characterized as apoptosis, autophagy, or a
novel type of PCD, primarily because the molecular machinery involved in these
processes remains largely uncharacterized in this group of organisms (7).
In addition to the relatively recent discovery that MTZ can induce PCD in B.
hominis, new data has emerged that is important for understanding the complete
picture of MTZ activation and resistance. First, it has been demonstated that activated
MTZ does not randomly bind to proteins in E. histolytica. Instead, MTZ reproducibly
binds to enzymes such as SOD, thioredoxin reductase, and thioredoxin, and to thiol
containing compounds such as cysteine (19). Second, it has been demonstrated that
recombinant E. histolytica thioredoxin reductase can reduce MTZ in vitro (19); these
authors obtained similar results when they tested recombinant T. vaginalis thioredoxin
reductase (18, 19). Therefore, metabolic pathways besides PFOR/Fdx may be involved
in MTZ activation.

Third, it has been noted that bacterial nim (nitroimidazole

reducatase) genes may be capable of detoxifying MTZ by adding a nitroso group to the
drug, which is later reduced to a non-toxic amine. E. histolytica and T. vaginalis also
harbor nim genes, and a recent study demonstrated that expression of recombinant
protozoal NIMs could induce MTZ resistance in E. coli (26). Although expression levels
of these genes did not correlate with MTZ resistance in either parasite, it is interesting
that E. histolytica may indeed be capable of evading killing by MTZ, even without
metabolic changes.
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MTZ resistance has been characterized in T. vaginalis, Giardia lamblia, and E.
histolytica, primarily by studying laboratory-induced resistant strains (36).

Not

surprisingly, metabolic changes were observed in MTZ resistant Trichimonas vaginalis
and Giardia. For example, PFOR and Fdx I were downregulated fivefold and sevenfold,
respectively, in MTZ-resistant Giardia (reviewed in (36)).

The levels of PFOR and Fdx

also decreased in MTZ laboratory strains of T. vaginalis (36).

Likewise, a MTZ-resistant

laboratory strain of E. histolytica displayed metabolic changes: MTZ-resistant E.
histolytica cells showed increased expression of SOD and peroxiredoxin. PFOR activity
was not reduced, but the expression level of Fdx 1 was reduced, similar to MTZ resistant
Giardia (36). Both Giardia and T. vaginalis have alternate metabolic pathways that can
be utilized to generate energy, but that do not activate MTZ (36); it is believed that E.
histolytica has no alternative metabolic pathways, and that this phenomenon has
prevented clinical MTZ resistance. If E. histolytica has no mechanism to circumvent MTZ
activation metabolically, how is it possible to induce MTZ resistance, even under
laboratory conditions? How do changes in levels of SOD and peroxiredoxin allow for
MTZ resistance in E. histolytica? The activation of MTZ is clearly not as straightforward
as once believed, and activation mechanisms may differ among cell types.
Besides metabolic changes that fail to activate drugs such as MTZ, cells can
utilize many mechanisms to evade chemotherapeutic agents. For example, cells can
prevent drug uptake, actively excrete drugs, circumvent drug targets, or increase the
efficiency of repair caused by drug damage (6). To this end, we tested some of these
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mechanisms in the MTZ resistant GFP-PHBTK cells. We tested the cells for MDR activity,
and found that three different E. histolytica mutants had statistically significant MDR
activity as compared to WT cells (Fig. 2.3). Because we did not observe MTZ resistance
in all three mutants, we do not believe that MDR activity caused the MTZ-resistant
phenotype observed in the cells expressing GFP-PHBTK. It is possible that long-term
exposure to selectable markers, G418 and hygromycin, or the inducing antibiotic,
tetracycline, triggered the MDR activity observed in these cells. It has been reported
that transient exposure to drugs, even those that are not considered substrates of Pgp
pumps, can induce the expression of Pgp and MDR genes in human cancer cell lines (9,
10).

Although not directly relevant to this study, this phenomenon should be

considered when treating mutant E. histolytica cell lines with drugs. We also looked for
metabolic changes observed in other laboratory strains of MTZ resistant E. histolytica
(e.g., levels of SOD). We observed minimal changes in SOD levels by western blot (Fig.
2.4). Although the presence of a second, smaller band in the “wildtype” lane suggests
that levels of SOD in cells expressing GFP or GFP-PHBTK may be slightly altered in
comparison to WT cells, the fact that this band was absent from both transgenic cell
lines indicates that this difference was not responsible for the MTZ resistance observed
in the cells expressing GFP-PHBTK. However, we have not yet examined the possibility
that levels of other enzymes known to be altered in MTZ resistant E. histolytica, such as
peroxiredoxin, were perturbed in the cells expressing GFP-PHBTK.
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Given that MTZ can induce PCD in B. hominis, and since PI3Ks play a role in PCD
signaling pathways in other cell types, we next examined the possibility that MTZ
induced PCD in WT E. histolytica cells (Figs. 2.5 and 2.7). We observed no obvious
changes in DNA condensation or cell size in four hours of incubation in MTZ, the time
point at which differences in killing percentages caused by MTZ were observed using
trypan blue staining (See Appendix D).

However, after 18 hours in MTZ, these

phenotypes were extremely noticeable (Fig. 2.5). We observed several different nuclear
staining patterns. In some cases, the DNA in the nucleus appeared condensed, and
other times, the nucleus displayed a web-like staining pattern. We often observed a
prominent ring around the nucleus. Several cells were observed with combinations of
these phenotypes. In contrast, the majority of cells incubated with an equivalent
volume of PBS (diluent control) for 18 hours displayed round, condensed nuclei. We
also observed a statistically significant drop in cell size after 18 hrs in MTZ; the MTZtreated cells were approximately half the size of the PBS control-treated cells (Fig. 2.7).
While this study may not be comprehensive enough to definitively identify MTZ as a PCD
stimulus in E. histolytica, we have shown evidence that this is the case.
In order to identify connections between inhibition of PI3K signaling and MTZinduced PCD, we repeated the microscopic study using cells expressing GFP-PHBTK.
Surprisingly, as compared to WT cells treated with MTZ, we observed no differences in
maintenance of nuclear integrity or stability of cell size when GFP-PHBTK cells were
treated with MTZ for 18 hours (Figs. 2.6 and 2.7). There are several possible reasons
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why we may have observed no “protection” from MTZ-induced PCD in GFP-PHBTK cells.
First, our characterization of PCD used microscopic observation of nuclei to distinguish
untreated and treated cells. While this was a straightforward method to distinguish
between cells with vastly different phenotypes, this method does not easily distinguish
between subtle changes in cells. Furthermore, there was a difference of only 10% in the
population of WT vs cells expressing GFP-PHBTK that were killed by MTZ. Although
statistically significant, this relatively small difference may not be immediately obvious
by microscopic examination of a population of cells. In addition, it has been reported
that any program of cell death is somewhat heterogeneous among any given cell
population (22), further confounding microscopic observations of an entire population
of cells. Second, changes in levels of MTZ-induced death, calculated by live:dead counts
of cells stained with trypan blue, were recorded after a four hour incubation period. It
is possible that after 18 hours, which is presumably “late” in a PCD program, there is less
of a difference in WT cells and those expressing GFP-PHBTK. In other words, it is possible
that inhibition of PI3K signaling simply delays the initiation of a PCD program: late stages
may appear similar in both types of cells. Therefore, it may be necessary to use a
molecular approach that can detect cellular “apoptotic” changes at earlier stages of PCD
in order to discern differences among the cell lines. Furthermore, other programs of cell
death, including autophagy, should be explored.

Entamoeba invadens utilizes

autophagy during encystation (27), and others have shown that both DNA damaging
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drugs (such as MTZ) (15) and reactive oxygen species (48) can induce autophagy in
mammalian cells.
Cells expressing GFP-PHBTK may also be protected from MTZ via undetermined
metabolic changes or by a novel mechanism that was not explored in this study. A study
using whole genome microarrays found that E. histolytica cells exposed to NO or H2O2
displayed several changes in gene expression; however, the majority of responding
genes corresponded to hypothetical proteins with unidentified function, suggesting that
the amoeba possesses novel pathways for responding to nitrosative and oxidative stress
(39). Therefore, microarray analysis of cells expressing GFP-PHBTK may help elucidate
the MTZ resistance mechanism in this cell line. Additionally, in-depth characterization
of the metabolism of cells expressing GFP-PHBTK may be necessary to understand its
MTZ resistance mechanism. Interestingly, treatment of E. histolytica with MTZ caused
the up- and down-regulation of genes involved in lipid metabolism (35), so it is not
unreasonable to expect that a lipid kinase could play a role in the mechanism of action
of MTZ.
Fortunately, MTZ resistance is clinically rare in E. histolytica (3-5). However, no
vaccine is currently available (14), and despite the development of new
chemotherapeutics (1, 2), MTZ remains the drug of choice for amoebiasis. Therefore, it
is important to completely understand the mechanisms of action of MTZ in E.
histolytica. It is tempting to assume that changes in metabolism identified in Giardia
and Trichimonas represent the primary resistance mechanisms for MTZ in all organisms,
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and that the absence of such metabolic changes in E. histolytica indicates that MTZ
resistance will not be a problem. However, Samuelson has stressed that there are
significant metabolic differences among MTZ-susceptible parasites (32). This seems to
be due in part to lateral gene transfer from multiple bacteria.

For example,

Methanosarcina barkeri seems to be the source of E. histolytica Fdx, while Desulfovibrio
desulfuricans possesses a Fdx most like that of Giardia. In addition, MTZ activation and
inactivation takes place in the cytosol of E. histolytica, but takes place in the
hydrogenosome in T. vaginalis (32). The microenvironments of these reactions may
subtly alter the mechanism of action of MTZ and any associated resistance mechanisms.
Finally, MTZ resistance varies with regard to environmental oxygen conditions: clinically
MTZ-resistant strains of T. vaginalis have been identified that are only resistant in
aerobic conditions.
Despite the potentially complex nature of MTZ resistance, it is important to
understand why overexpression of PHBTK domains in E. histolytica could increase MTZ
resistance. Assuming inhibition of PI3K signaling in this cell line is responsible for the
phenotype, new MTZ mechanisms related to this pathway may be discovered. To the
best of our knowledge, we have shown for the first time that inhibition of PI3K can
induce MTZ resistance, and that MTZ can induce PCD in E. histolytica. Most importanty,
this cell line represents the possibility that relatively minor changes in gene expression
could lead to clinically MTZ resistant strains of E. histolytica.
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Future Studies
In order to completely understand the involvement of PI3K signaling in MTZ
resistance in E. histolytica, we will need a better understanding of these individual
pathways. For example, what are the interacting partners of PI3K and its product, PIP3,
in E. histolytica? Assuming the AKT pathway is conserved in E. histolytica, what happens
to MTZ resistance if AKT signaling is disrupted? Is the PI3K pathway in E. histolytica
related to a program of PCD? Which proteins are involved in the putative PCD pathway?
What is the timeline of PCD in E. histolytica? Does treatment with MTZ alter PCD
pathways? Do cells expressing GFP-PHBTK have changes in the PCD pathway or changes
in metabolic pathways that might prevent activation of MTZ?

Are E. histolytica cells

expressing GFP-PHBTK resistant to other imidazole drugs? While answering each of these
questions will be a complex process, the results will be important for addressing any
future problems with MTZ resistance in E. histolytica, and possibly other protozoans,
and will be critical for the development of new amoebiasis therapies.
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Appendix A
Localization of PIP3 in E. histolytica using a GST-PHBTK PIP3 biosensor and a PIP3 antibody

Figure A.1. PIP3 predominantly localizes to the plasma membrane in WT E. histolytica.
WT E. histolytica cells were stained with purified recombinant (Ai) GST (control) or (Aii)
GST-PHBTK protein and a fluorescent anti-GST antibody. Corresponding DIC images are
also shown (Aiii, Aiv). Cells incubated with GST did not exhibit staining, while cells
incubated with GST-PHBTK showed uniform staining of the plasma membrane (data
collected by Y.A. Byekova). B. WT E. histolytica cells were also stained with a
commercially available antibody to PIP3 and a secondary fluorescent anti-mouse
antibody. Similar to the cells stained with GST-PHBTK, the periphery of the cells was
uniformly decorated with PIP3 antibody (Bi). This pattern was observed in nearly all of
the cells (Bii), but no staining was observed in cells incubated only with the secondary
antibody (Biii). Corresponding DIC images are also shown (Biv, Bv, Bvi) (data collected
by R.R. Powell). Together, these data suggest that GST-PHBTK is a valuable tool for
assessing PIP3 localization in E. histolytica cells.
Data from Figure A.1 Part A appears in the August 2008 Clemson University Biological
Sciences MS Thesis by Y.A. Byekova entitled “Characterization of phosphatidylinositol
(3,4,5)-trisphosphate subcellular localization during endocytosis in Entamoeba
histolytica.” Data from Figure A.1, Parts A and B, are part of the upcoming publication:
Byekova, Y. A., R. R. Powell, B. H. Welter, and L. A. Temesvari. 2009. Localization of
phosphatidylinositol (3,4,5)-trisphosphate to phagosomes in Entamoeba histolytica
achieved using GST- and GFP-tagged lipid biosensors. Infect Immun.
doi:10.1128/IAI.00719-09.
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Appendix B
Construction and validation of an E. histolytica cell line expressing GFP

Figure B.1. Construction and validation of an E. histolytica cell line expressing GFP.
In order to construct an E. histolytica cell line that expressed GFP, we used PCR to
amplify EGFP (enhanced GFP) from a commercially available plasmid, pEGFP-N1
(Clontech). The amplified DNA was subcloned into the pCR2.1 TOPO plasmid vector
(Invitrogen, Carlsbad, CA), and was subsequently ligated into the E. histolytica
expression vector, pGIR209, which encodes a tetracycline (tet) operator and confers
G418 resistance (2). A. Log phase E. histolytica cells were stably transfected as
described (4) with pGIR209 harboring GFP, in addition to a second plasmid, pGIR308,
which encodes a tet repressor, and confers hygromycin resistance (2). The dual plasmid
system (gift of Dr. W.A. Petri, University of Virginia, Charlottesville, VA) allows for tetinducible expression of exogenous proteins in E. histolytica (2). Expression of exogenous
proteins was induced by the addition of 5 µg/mL tet to the culture medium for 24 hours.
B. Expression of GFP was verified by western blot analysis of E. histolytica cell lysates as
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described (3). WT cells (B1) and cells induced to express GFP (B2) were incubated with
mouse anti-GFP antibodies (Invitrogen). Cells expressing GFP harbored a unique protein
band of approximately 30 kDa, corresponding to the predicted size of GFP. C.
Expression of GFP was also verified using live cell imaging. WT E. histolytica cells or cells
induced to express GFP were chilled to remove them from the glass, centrifuged, and
washed twice in PBS to reduce background fluorescence caused by components in the
culture medium. Cells were resuspended in a solution of glycerol:PBS (1:1), mounted in
a Lab-Tek coverglass slide (Nalge Nunc International, Rochester, NY), and observed using
a Zeiss LSM 510 confocal microscope. Background fluorescence was observed in WT
cells (Ci, Ciii; fluorescence images in left panels, DIC images in right panels), while cells
induced to express GFP (Cii, Civ; fluorescence images in left panels, DIC images in right
panels) displayed high fluorescence intensity when observed at microscope settings
identical to those used to image WT cells. Together, these data suggest that the E.
histolytica cell line expressing GFP is authentic.
E. histolytica cells expressing GFP were constructed and validated by R.R. Powell. E.
histolytica cell lines expressing GFP-PHBTK (cell line constructed by Y.A. Byekova) (1) or
EhRabA-Q84L (cell line constructed by B.H. Welter) (4) were constructed using similar
techniques and the same dual plasmid system. Data from Figure B.1, Part B is part of
the upcoming publication, reference #1, listed below.
REFERENCES
1. Byekova, Y. A., R. R. Powell, B. H. Welter, and L. A. Temesvari. 2009. Localization of
phosphatidylinositol (3,4,5)-trisphosphate to phagosomes in Entamoeba histolytica
achieved using GST- and GFP-tagged lipid biosensors. Infect Immun.
doi:10.1128/IAI.00719-09.
2. Ramakrishnan, G., R. R. Vines, B. J. Mann, and W. A. Petri Jr. 1997. A tetracyclineinducible gene expression system in Entamoeba histolytica. Mol. Biochem.
Parasitol.84:93-100.
3. Welter, B. H., R. C. Laughlin, and L. A. Temesvari. 2002. Characterization of a Rab7like GTPase, EhRab7: a marker for the early stages of endocytosis in Entamoeba
histolytica. Mol. Biochem. Parasitol.121:254-264.
4. Welter, B. H., and L. A. Temesvari. 2009. Overexpression of a mutant form of
EhRabA, a unique Rab GTPase of Entamoeba histolytica, alters endoplasmic reticulum
morphology and localization of the Gal/GalNAc adherence lectin. Eukaryot. Cell.8:10141026.
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Appendix C
Measurement of endocytosis and adhesion in cells expressing GFP-PHBTK

Figure C.1. Measurement of endocytosis and adhesion in cells expressing GFP-PHBTK.
Few cells expressing GFP-PHBTK were observed engulfing erythrocytes (1); therefore, this
endocytic process was assessed quantitatively in cells expressing GFP-PHBTK, WT cells,
and a control cell line expressing GFP. A. Cells expressing GFP-PHBTK displayed inhibited
erythrophagocytosis. Red blood cell uptake levels in cells expressing GFP-PHBTK were
approximately 20% of WT levels, an extremely significant difference (***, P < 0.001)
(data collected by Y.A. Byekova). Because ligand binding is an important first step in
phagocytosis, inhibited erythrophagocytosis can be attributed to reduced adhesion of
red blood cells to the E. histolytica membrane. B. Adhesion of erythrocytes to the
surface of E. histolytica cells was quantified. No significant differences were observed
among the three cell lines, suggesting that expression of GFP-PHBTK did not alter cell
adhesion (quantification performed by R.R. Powell). In order to determine if multiple
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endocytic trafficking pathways were disrupted in cells expressing GFP-PHBTK, uptake of
two additional endocytic markers, FITC-dextran and FITC-holo-transferrin (FITC-HTf),
was assessed. It has been reported that uptake of red blood cells, dextran, and the ironbound protein, HTf, relies on different endocytic machinery (2). Because FITC and GFP
exhibit similar excitation and emission spectra, individual “Time 0” blank samples were
collected for individual cell lines and were subtracted from subsequent fluorescence
readings. C. Pinocytosis of fluid-phase was not inhibited in cells expressing GFP-PHBTK
(measurements performed by Y.A. Byekova). D. Uptake of FITC-HTf was significantly
inhibited in cells expressing GFP or GFP-PHBTK as compared to WT cells (data obtained
by R.R. Powell). However, the two GFP-expressing cell lines displayed no significant
differences in FITC-HTf uptake levels as compared to one another. Although we cannot
rule out the possibility that expression of GFP-PHBTK inhibits uptake of FITC-HTf, we do
not favor this explanation because control cells expressing GFP also exhibited reduced
uptake of this endocytic marker. It is possible that, similar to increased activity of
multidrug resistance pumps (see Chapter 2), long-term exposure to selection agents,
G418 and hygromycin, affected uptake of FITC-HTf. Together, these data suggest that
PI3Ks likely play a role in erythrophagocytosis, but not related adhesion events and
other endocytic processes, in E. histolytica.
Data from Figure C.1, Parts A and C, appears in the August 2008 Clemson University
Biological Sciences MS Thesis by Y.A. Byekova entitled “Characterization of
phosphatidylinositol (3,4,5)-trisphosphate subcellular localization during endocytosis in
Entamoeba histolytica.” Data from Figure C.1, Parts A, B, and C is part of the upcoming
publication, reference #1, listed below.
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Appendix D
Microscopic examination of E. histolytica cells after a four hour metronidazole
incubation

Figure D.1. WT E. histolytica cells and cells expressing GFP-PHBTK did not display altered
nuclear morphology after four hours in MTZ.
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Cells were incubated with PBS (A, B, C, G, H, I) or MTZ (D, E, F, J, K, L) for four hours and
stained with Hoescht (A, D, G, J) and propidium iodide (B, E, H, K) as described in
Chapter 2. DIC images are also shown (C, F, I, L). WT cells and cells expressing GFP-PHBTK
exhibited similar nuclear morphology after incubation in PBS or MTZ. Nuclear
fragmentation and condensation (J) was occasionally observed in both types of cells
after 4 hours in MTZ; however, most of the nuclei were round and staining was
consistent throughout the nuclei. Interestingly, the overall morphology of the cells was
affected after 4 hours in MTZ. Both WT cells and cells expressing GFP-PHBTK were round
in overall appearance (F, L) as compared to the amoeboid morphology displayed by cells
incubated in PBS (C, I). Data collected by R.R. Powell.
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